Fatemeh Goharriz

Fatemeh Goharriz

Auto-generated profile, based on publicly available information

Fatemeh Goharriz

Endocrinology, and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RSReza Sinaei
Reza Sinaei
MNMohammad Javad Najafzadeh
Mohammad Javad Najafzadeh
SGSomayeh Ghafari
Somayeh Ghafari
AHAli Hosseininasab
Ali Hosseininasab
APAbbas Pardakhty
Abbas Pardakhty
FGFatemeh Goharriz
Fatemeh Goharriz
Background: Several coronavirus disease 2019 (COVID-19) vaccines, utilizing different platforms, have successfully obtained emergency clinical use authorization to prevent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections. Most published data from COVID-19 vaccine trials have frequently observed mild-to-moderate side effects, with varying severity depending on various vaccine types. Objectives: This study aimed to estimate the prevalence of side effects associated with four types of COVID-19 vaccines among vaccinated healthcare workers following the first and second vaccine doses and to identify possible risk factors for COVID-19 vaccine side effects. Methods: This cross-sectional study was conducted from April 2021 to March 2022 by administering a questionnaire and conducting direct interviews with healthcare workers in Kerman, southeastern Iran, who had received 2 or more doses of COVID-19 vaccines. Results: Out of 861 individuals enrolled in the study, 38.7% received Sputnik, 32.4% AstraZeneca, 19.6% Covaxin, and 9.3% Sinopharm vaccines. Overall, the most common side effects after the first and second doses included general symptoms, fever and chills, injection site reactions, neurological symptoms, and gastrointestinal symptoms. Furthermore, the frequency of symptoms significantly reduced after the second dose. Conclusions: General symptoms and injection site reactions were significantly more common after receiving the first dose of vaccines compared to the second dose. No severe vaccine side effects were observed in this study. However, further research is required to evaluate the long-term symptoms and safety profiles of COVID-19 vaccines.

1 February 2024 in Current Respiratory Medicine Reviews
Verified
Journal Article
Closed access
PDF file
MFMitra Samareh Fekri
Mitra Samareh Fekri
FSFaranak Salajegheh
Faranak Salajegheh
MRMohammad Rezaei Zadeh Rukerf
Mohammad Rezaei Zadeh Rukerf
MNMohsen Nakhaie
Mohsen Nakhaie
MBMaliheh Sadat Bazrafshani
Maliheh Sadat Bazrafshani
MMMohammad Sadegh Shahmoradzadeh Miri
Mohammad Sadegh Shahmoradzadeh Miri
Background and Objective: Respiratory complications of COVID-19 should be considered as critical concerns that require prompt medical intervention. The aim of this study was to examine the impact of COVID-19 on pulmonary function and quality of life among recovered patients through a three-month follow-up period. Methods: This pilot study aimed to assess the pulmonary functions and quality of life in 32 COVID-19 survivors at Afzalipour Hospital, Kerman, Iran. Pulmonary functions were evaluated using spirometry to evaluate FVC, FEV1, PEF, and FEV1/FVC. Quality of life was measured using the SF-36 questionnaire, which evaluated eight health-related concepts. Statistical analysis was performed using SPSS v23. Results: Among the 32 survivors of COVID-19, 41.6% and 59.4% were male and female, respectively. The mean length of hospitalization for admitted patients (56.3% of all patients) was 10.89 days. Male survivors exhibited significantly lower values in FEV1 (3.06 vs. 4.05, p = 0.02), PEF (6.45 vs. 10.58, p = 0.002), and FEF-25-75 (3.17 vs. 4.94, p = 0.008) compared to healthy males of the same age. For female survivors, all pulmonary indices were significantly lower than healthy females of the same age. Regarding quality of life, there was no statistical significance between male and female survivors. However, when compared with healthy populations, survivors obtained lower scores in various quality-of-life items. Male survivors had notably lower scores in physical functioning (3.17 vs. 4.94, p = 0.008) and physical role (40.38 vs. 73.8, p = 0.008). Female survivors scored considerably lower than the healthy population in all quality of life items, except for role emotional and mental health. Conclusion: COVID-19 survivors had lower pulmonary indices and quality of life compared to healthy individuals of the same sex and age, with female survivors exhibiting worse conditions.